Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A., Garber, Jeffrey R., Garvey, W. Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B., Jellinger, Paul S., McGill, Janet B., Mechanick, Jeffrey I., Rosenblit, Paul D., Umpierrez, Guillermo E.·2019·Endocrine Practice
DOI 10.4158/cs-2018-0535

Cited by (296)

Items 201–296 of 296

  1. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study
    Li Zang, Han Yin, Lixian Chen, HU Da-qing, Hui Jin, Nailong Yang, Xiaoyun Shi, Linlang Liang, Mingming Liu, Hong Song Fan et al. · 2019 · Diabetes Therapy
  2. Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting—the GOAL_RO trial
    for the GOAL_RO Study Group, Daniela Stegaru, Simona Nicodim, Delia Vladu, Olimpia Guțu, Adriana Gabriela Onaca, Florina Pîrvu, Mihaela Moise, Cristian Guja · 2021 · Annals of Translational Medicine
  3. Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks
    Yu-Cheng Kao, Tien‐Hsing Chen, Chi‐Hung Liu, Jawl‐Shan Hwang, Ching-Chung Hsiao, Yu‐Sheng Lin, Chun‐Tai Mao, Ming‐Jui Hung, Yanrong Li · 2021 · Scientific Reports
  4. Creatine Supplementation in Type 2 Diabetic Patients: A Systematic Review of Randomized Clinical Trials
    Ana Luiza Cabrera Martimbianco, Marcella Mancini de Sousa, M Nakata, Carlos Eduardo Slateff Baldini, Elizabeth Barbosa Oliveira‐Sales, Mírian Aparecida Boim, Edgar Maquigussa · 2021 · Current Diabetes Reviews
  5. Comparative Effectiveness of Oral Hypoglycemic Agents for Glycemic Control and Glycemic Variability in Patients with Type 2 Diabetes Mellitus: Using Flash Glucose Monitoring
    Poongothai Venkatachalapathy, Karthik Kumar Dos Alagarswamy Mohandoss, Murali Munisamy, Mohan Sellappan · 2024 · Current Diabetes Reviews
  6. Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs.
    AG Unnikrishnan, Banshi Saboo, Shashank Joshi, Jothydev Kesavadev, B. M. Makkar, Sanjay Agarwal, S R Aravind, Krishna Seshadri, Manoj S Chawla, Neeta Deshpande et al. · 2019 · PubMed
  7. Injectable combination therapies for the management of diabetes: an Indian perspective
    Deep Dutta, Deepak Khandelwal, Sanjay Kalra · 2020 · Expert Opinion on Drug Metabolism & Toxicology
  8. Values informing the development of an indicator of appropriate diabetes therapy: qualitative study
    Christina M. LaVecchia, Víctor M. Montori, Nilay D. Shah, Rozalina G. McCoy · 2020 · BMJ Open
  9. Liu Wei Di Huang Wan and the Delay of Insulin Use in Patients with Type 2 Diabetes in Taiwan: A Nationwide Study
    Hsin-Hung Chen, Chien‐Tung Wu, Yueh‐Ting Tsai, Chun-Wei Ho, Ming‐Chia Hsieh, Jung‐Nien Lai · 2021 · Evidence-based Complementary and Alternative Medicine
  10. Conceptos Actuales de la Terapia Con Insulina.
    Guillermo Jiménez Montero, Mayra Villegas Barakat, María L. Carvajal Solórzano · 2022 · Revista Ciencia y Salud Integrando conocimientos
  11. Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program
    Carlos Morillas, Javier Escalada, Rafael Palomares, Diego Bellido, Fernando Gómez Peralta, Antonio Pérez · 2019 · Diabetes Therapy
  12. Transcultural Lifestyle Medicine
    Ramfis E Nieto-Martínez, Juan Pablo Gonzalez-Rivas · 2020 · Springer eBooks
  13. X-box binding protein 1: A new metabolic mediator and drug target of metformin?
    Kai Lou, Pei Sun, Chunxue Zhang, Qiang Jiang, Shuguang Pang · 2022 · Frontiers in Pharmacology
  14. Pharmacologic Management of Human Immunodeficiency Virus and Common Chronic Conditions
    Courtney J. Pitts, Angelina Anthamatten · 2019 · The Journal for Nurse Practitioners
  15. Diabetes rescue, engagement, and management (D-REM) for hypoglycemia: Clinical trial protocol of a community paramedic program to improve diabetes management among adults with severe hypoglycemia
    Sumit Bhagra, Allison Ducharme‐Smith, Michael B. Juntunen, Chad P. Liedl, Elizabeth H. Golembiewski, Wendy J. S. Sundt, Tami S. Krpata, Michelle A. Lampman, Anna L. Espinoza, Rozalina R. McCoy · 2025 · PLoS ONE
  16. Comparative cardiovascular effects of GLP ‐1 agonists using real‐world data
    Amisha Wallia, Matthew James O’Brien, Stephanie Hakimian, Raymond H. Kang, Andrew Cooper, Nicola Lancki, John J. Stephen, Cassandra Aikman, David T. Liss, Emily D. Parker et al. · 2023 · Endocrinology Diabetes & Metabolism
  17. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Anne D. Misher, Andrea Ampuero, Rebecca Phan, Soma Aziz, Eti Ebong, Judy Braich, Kristin Dyches, Robin L. Southwood · 2020 · American Journal of Therapeutics
  18. Nuclear magnetic resonance technology and clinical applications
    Deanna D.H. Franke, Margery A. Connelly · 2020 · Elsevier eBooks
  19. Glycaemic Control in People with Type 2 Diabetes Treated with Insulin Degludec: A Real-World, Prospective Non-interventional Study—UPDATES Saudi Arabia
    Mussa Almalki, Hossam Aldesokey, Dania Alkhafaji, Abdulrahman Alsheikh, Uffe Christian Braae, Lars Lang Lehrskov, Waleed Magawry, Moataz Yahia, Ahmed Haroun · 2022 · Advances in Therapy
  20. New technical approach to the diabetes therapy
    Klemen Dovč, Tadej Battelino · 2020 · Minerva Pediatrics
  21. Diabetes and Treatments
    Milan M. Obradovic, Emina M. Sudar-Milovanovic, Zoran M. Gluvic, Takashi Gojobori, Magbubah Essack, Esma R. Isenović · 2020 · Springer eBooks
  22. Introduction: Real-World Evidence in Type 2 Diabetes
    Mohamed M. Hassanein, Aslam Amod, Kamlesh K. Khunti, Moon‐Kyu Lee, Viswanathan Mohan · 2020 · Diabetes Therapy
  23. Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and a Sulfonylurea in a Real-World Setting
    Natalie Aboubechara, Vittoria Marie Ledesma, Fang Niu, Susan M. Lee, Yesha A. Patel, Mirta Millares, Rita L. Hui · 2020 · The Permanente Journal
  24. Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review
    Antonio Ruiz‐García, Vicente Pallarés‐Carratalá, Adalberto Serrano-Cumplido, Carlos Escobar-Cervantes, Alfonso Barquilla-García, J.A. Divisón, Miguel Turégano-Yedro, Miguel Ángel Prieto-Díaz, Sergio Cinza‐Sanjurjo, F. Javier Alonso-Moreno et al. · 2022 · Medicina de Familia SEMERGEN
  25. Glycemic control and outcome after carotid intervention in patients with T2D: A Swedish nationwide cohort study
    Alexander Zabala, Anders Gottsäter, Marcus Lind, Björn Eliasson, Rebecka Bertilsson, Jan Ekelund, Magnus Jonsson, Thomas Nyström · 2023 · Diabetes and Vascular Disease Research
  26. Multidisciplinary approach and combination pharmacotherapy for the management of cardiometabolic patients
    Giuseppe M.C. Rosano, Cristiana Vitale, Ilaria Spoletini, Kamlesh K. Khunti, Kostantinos Tsioufis, Sarah Onida, Marisa Papaluca, Alberto Zambon · 2025 · Journal of Cardiovascular Medicine
  27. An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
    Dhiren K Patel · 2020 · Journal of Clinical Pharmacy and Therapeutics
  28. Comprehensive Management of Diabetes Mellitus in the Elderly: A Review
    Bharat Kumar, Ravi Kant, Gopal Krishana Bohra · 2025 · Journal of Cardio-diabetes and metabolic disorders
  29. Evidence-based pharmacological investigation of the clinical practice and rational use of metformin in prediabetes mellitus
    Donghu Liu, Xiaoying Chen, Qianyun Wang, Xingru Pan, Xuehan Wei, Bohong Wang, Ying Wang, Xue Xue, Chunli Lu · 2025 · Precision medication.
  30. GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists
    Betsy A. Gillenwater, Andrew N. Wakefield, Jessica S. Triboletti, Jasmine D. Gonzalvo, Ashley H. Meredith · 2019 · AADE in Practice
  31. Transitioning to non-insulin therapy in a patient receiving high dose insulin
    Basem M. Mishriky, Doyle M. Cummings, Carlos E. Mendez, Shivajirao Prakash Patil, James R. Powell · 2020 · Journal of the American Association of Nurse Practitioners
  32. Relationship of Glucose Variability and Daily Lifestyle by Continuous Glucose Monitoring (CGM)
    Yamashita H, Yoshihisa Kato, Hiroshi Bando, Kanazawa S, Tanaka M, Etsuko Sueki, Kanagawa H, Takafumi Kawata, Atsuko Kawahito, Aihara A et al. · 2020 · Asploro Journal of Biomedical and Clinical Case Reports
  33. Development and Internal Validation of A Prediction Tool To Assist Clinicians Selecting Second-Line Therapy Following Metformin Monotherapy For Type 2 Diabetes
    Caroline E. El Sanadi, Kevin M. Pantalone, Xinge Ji, Michael W. Kattan · 2020 · Endocrine Practice
  34. Blood Glucose and Insulin Values on Daily Profile, M Value and Meal Tolerance in Patients with Type 2 Diabetes Mellitus (T2DM)
    Yozo Takehisa, Hiroshi Bando · 2020
  35. Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea
    Hye Soon Kim, Jae Myung Yu, Hak Chul Jang, Eui Kwang Choi, Jeong Hyun Park, Ho Sang Shon, Choon Hee Chung, Keun‐Gyu Park, Jae‐Hyoung Cho, Won Kim et al. · 2022 · Diabetes Metabolic Syndrome and Obesity
  36. Ertugliflozin in type 2 diabetes: a profile of its use
    Lesley J. Scott · 2019 · Drugs & Therapy Perspectives
  37. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
    Andrej Janež, Petra Örsy, Karolina Stachlewska, Karen Salvesen‐Sykes, Liana K. Billings, Athena Philis‐Tsimikas · 2019 · Diabetes Obesity and Metabolism
  38. Cardiovascular Health Risk Assessment and Primary Prevention of Atherosclerotic Cardiovascular Disease
    Melvyn Rubenfire, Richard Lawrence Weinberg, Sina Jamé, Elif A Oral, Kenneth Jamerson, Robert D. Brook · 2020 · Journal of Clinical Cardiology and Cardiovascular Therapy
  39. Blood pressure targets: comparing lower versus standard targets for people with hypertension
    Oliver Hamer, James Edward Hill, Joanna Harrison · 2021 · British Journal of Cardiac Nursing
  40. Solutions thérapeutiques pour un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine
    André Jacques Scheen · 2019 · Médecine des Maladies Métaboliques
  41. Lessons Learned from Recent Clinical Trials Targeting Diets to Treat and Prevent Obesity and Diabetes
    Nicholas Wright · 2020 · Royal Society of Chemistry eBooks
  42. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens
    Shannon L. Castek · 2022 · Federal Practitioner
  43. Modifiable Comorbidity as a Risk Factor for DRPs and Unimproved NIHSS Score in Ischemic Stroke Patients
    Firdha Aprillia Wardhani · 2023 · Pharmacology and Clinical Pharmacy Research
  44. Durability of glycaemic control in patients with type 2 diabetes after metformin failure: Prognostic model derivation and validation using the DISCOVER study
    Suping Ling, Ping Sun, Francesco Zaccardi, Sajan Khosla, Andrew Cooper, Peter Fenici, Kamlesh Khunti · 2020 · Diabetes Obesity and Metabolism
  45. Noninsulin Therapy for Diabetes
    Rebecca Maxson, Emily K. McCoy · 2020 · Physician Assistant Clinics
  46. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias
    Leopoldo Pérez de Isla, L. Masana, Rosa M. Argüeso, Raquel Campuzano, Isabel Egocheaga, Carlos Escobar, Lorenzo Fácila, Pedro Mata López, Miriam Rossi, Carmen Rus Mansilla et al. · 2020 · Revista Española de Cardiología (English Edition)
  47. Vascular Complications in Type 2 Diabetes
    Chih Hao Chen-Ku · 2020 · Springer eBooks
  48. Patterns of drug use among type 2 diabetic patients with comorbidities attending a tertiary centre in Lagos Nigeria
    Adedunni Wumi Olusanya · 2021 · Clinical Diabetology
  49. [Integrated Care Protocol: Chronic complications of diabetes mellitus 2].
    Juan Humberto Medina-Chávez, Manuel Vázquez-Parrodi, Denisse Lizeth Santoyo-Gómez, Jaime Azuela Antuna, Juan C. Garnica-Cuéllar, Alejandro Herrera-Landero, Alejandra Balandrán · 2022 · PubMed Central
  50. Fable « L’exception française et les SGLT2-i ». Où se situe la perte de chance ?
    S. Halimi · 2019 · Médecine des Maladies Métaboliques
  51. New therapies for diabetes mellitus
    Michelangela Barbieri, Vittoria Cataldo, George T. Griffing, Giuseppe Paolisso · 2022 · Wiley eBooks
  52. Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
    Pablo Toledo Frías, Raquel Campuzano Ruíz, José Antonio Alarcón Duque, Alejandro Berenguel Senén, María Rosa Fernández Olmo, Manuel Abeytua Jiménez · 2019 · REC CardioClinics
  53. Integrating the 2019 AGS Beers Criteria into NP practice
    Kristene C. Diggins · 2020 · The Nurse Practitioner
  54. Which person with diabetes should receive cardioprotective glucose‐lowering medicines?
    Zachary T. Bloomgarden · 2020 · Journal of Diabetes
  55. Variants in STAU2 associate with metformin response in a type 2 diabetes cohort: a pharmacogenomics study using real-world electronic health record data
    Yanfei Zhang, Ying Hu, Kevin Ho, Dustin N. Hartzel, Vida Abedi, Ramin Zand, Marc S. Williams, Ming Ta Michael Lee · 2020 · medRxiv
  56. A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA
    Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, ROBERT J. CHILTON · 2020 · Cardiovascular Endocrinology & Metabolism
  57. Improving Dietary Recommendations for Patients With Type 2 Diabetes and Obesity in an Endocrinology Clinic
    Juan Jose Delgado-Hurtado, Erika L. Kline, Andrew Robert Crawford, Auden C. McClure · 2020 · Clinical Diabetes
  58. Paradigm shift in the management of DM & CVD —preventing the next CV event
    Yehuda Handelsman, Zachary T. Bloomgarden · 2020 · Journal of Diabetes
  59. Assessing the quality of the evidence underlying recommendations in type 2 diabetes’ commonly used clinical practice guidelines
    Enrik Enchev, Mariona Esteve-Serra, Luz María Reyes Céspedes, Rebeca Barahona San Millan, Mònica Recasens-Sala, Lidia Sojo-Vega, Elisabet Costa-Lima, José Manuel Fernández‐Real, Wifredo Ricart, Mercè Fernández-Balsells · 2020 · International Journal of Evidence-Based Healthcare
  60. Atuação de uma equipe multidisciplinar e os cuidados de enfermagem em um grupo de extensão de antitabagismo na Atenção Primária
    Matheus Gomes Andrade, Dilene Fontinele Catunda Melo, Ana Luiza Machado, Herllen Bárbara Ferreira Norte, Francisca Nellie de Paula Melo · 2020 · Editora Poisson eBooks
  61. Infecções Urinárias: Uma análise descritiva acerca do assunto junto ao grupo da terceira idade do Centro de Convivência do Idoso em São José dos Quatro Marcos – MT
    Rafael Rodrigues Gomides, Ligia Karla dos Santos Rezende, Marilza Garcia de Oliveira, Rosivania Aparecida dos Santos Rezende, Victória Bandeira dos Santos · 2020 · Editora Poisson eBooks
  62. Short Term Use of Empagliflozin Does Not Improve Left Ventricular Function in Non-Diabetic Hypertensive Patients: Results from a Non-Randomised Controlled Trial
    Liliane Mfeukeu‐Kuate, Jean-Claude Njabou Katte, Krystel K. EBO, Jean Claude Mbanya, Eugène Sobngwi · 2020 · World Journal of Cardiovascular Diseases
  63. Pilot Study: Evaluating the Impact of Pharmacist Patient-Specific Medication Recommendations for Diabetes Mellitus Therapy to Family Medicine Residents
    Camlyn Masuda, Rachel Randall, Marina Ortiz · 2020 · Pharmacy
  64. Effective Xultophy administration to stable blood glucose profile by Continuous Glucose Monitoring (CGM)
    Etsuko Sueki, Hiroshi Bando, Yoshikane Kato, Setsuko Kanazawa, Mayumi Tanaka, Hiroe Kanagawa, Takafumi Kawata, Atsuko Kawahito, Aya Aihara · 2020 · Institutional Repositories DataBase (IRDB)
  65. Modern Aspects of the Clinic, Diagnosis and Treatment of Prediabetes
    Пырикова Наталья Викторовна, И. В. Осипова, I. G. Polyakova · 2020 · The Russian Archives of Internal Medicine
  66. Pharmacological Management Evolution of Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials from 2013 to 2020 and Their Impact on Practice Guidelines
    Morales-Villegas EC · 2020 · Journal of Heart Health
  67. The Association Between Age at Diagnosis of Type 2 Diabetes and Albuminuria in Chinese Adults
    Shujing Wu, Shanshan Liu, Zhiyun Zhao, Mian Li, Tiange Wang, Shuangyuan Wang, Min Xu, Yuhong Chen, Meng Dai, Di Zhang et al. · 2020 · Research Square
  68. Sympathetic overdrive in patients with impaired carbohydrate metabolism
    M. М. Ordyan · 2020 · Medicine of Ukraine
  69. Nomogram to Predict Successful Septal Collateral Crossing during Percutaneous Coronary Intervention of Chronic Total Occlusion by retrograde approach: The Sep-CTO score
    Tong Liu, Yuchao Zhan, Zheng Wu, Yun Lv, Wenzheng Li, Jinghua Liu · 2021 · Research Square
  70. To study association of Neutrophil- Lymphocyte ratio with vascular complications in Type-2 Diabetes
    Shilpa Tumkur Andane Gowda, Shahari Hegde Kusumakar, Raveendra KR, Maraludevanapura Govindaiah Rohith · 2021 · Asian Journal of Medical Sciences
  71. Effects of healthcare system distrust on cognition in African American older adults with type two diabetes mellitus
    Jessica L Bergner · 2022 · MOspace Institutional Repository (University of Missouri)
  72. Evaluation of hyperalgesic effect of sitagliptin in albino mice
    Lalit Mohan, Manoj Kumar, Manish Kumar, Saajid Hameed, Amritanshu Shekhar · 2021 · IP International Journal of Comprehensive and Advanced Pharmacology
  73. Branched-chain amino acids and trimethylamine N-oxide as biomarkers of cardiometabolic outcomes
    Jose Luis Flores-Guerrero · 2021 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  74. Comparison of gastric motility in patients of type 2 diabetes mellitus with various degrees of glycemic control
    VandanaKumar Dhingra, Sanchay Jain, Ravi Kant, Ranjeeta Kumari · 2021 · World Journal of Nuclear Medicine
  75. Comentarios a la guía ESC/EAS 2019 sobre el tratamiento de las dislipemias
    Grupo de Trabajo de la SEC para la guía ESC 2019 sobre el tratamiento de las dislipemias, Revisores expertos para la guía ESC 2019 sobre el tratamiento de las dislipemias y Comité de Guías de la SEC · 2020 · Revista Española de Cardiología
  76. Hosszú hatású GLP-1-receptor-agonista szokatlan mellékhatása – a gastrointestinalis motilitás klinikai panaszokat okozó csökkenése IDegLira‑kezelés során – esetismertetés|
    Krisztina Arapovicsné Kiss, Lilla Borbáth, Péter Hajós, János Tibor Kis, Gábor Winkler · 2019 · Diabetologia Hungarica
  77. Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardiaca
    Vicente Arrarte, Raquel Campuzano, Amelia Carro, Almudena Castro, Regina Dalmau, Miriam Sandín, Elisa Velasco, Alfonso Valle · 2019 · REC CardioClinics
  78. “Incorporating a Gym Facility in a Lifestyle Medicine Practice for Patients with Diabetes Mellitus”
    Karl Z. Nadolsky, Austin Baraki, Spencer Nadolsky · 2022 · American Journal of Lifestyle Medicine
  79. Recent Advances in Oral Insulin Therapy by Nanoparticulate Drug Delivery Systems: Systematic Review
    Tuğçe TURAN, N. Başaran Mutlu Ağardan · 2022 · Journal of Literature Pharmacy Sciences
  80. The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
    Natalya Al'bertovna Chernikova, Liudmila L. Kamynina, Ametov As, D. A. Sychov · 2022 · Diabetes Mellitus
  81. Association between Controlling Nutritional Status Score and Severity of Coronary artery stenosis in elderly patients
    Guofu Zhong, Mingtai Chen, Junteng Chen, Mujuan Xu, Yue Han, Xiao Chang, Ling Men, Ling Wang · 2023 · Research Square
  82. Experience of Using Sodium-dependent Glucose Cotransporter Type 2 Inhibitors in Comorbid Patients in Real Clinical Practice
    Н. А. Кравчун, Інна Дунаєва, Kravchun PP · 2023 · Acta Scientific Gastrointestinal Disorders
  83. ЩОДО УПЕРЕДЖЕННЯ УСКЛАДНЕНЬ ЦУКРОВОГО ДІАБЕТУ 2 ТИПУ В ПРАКТИЦІ ЛІКАРЯ ЗАГАЛЬНОЇ ПРАКТИКИ - СІМЕЙНОГО ЛІКАРЯ
    Тетяна Ніколаєнко-Камишова, Ірина Височина · 2023 · Перспективи та інновації науки
  84. An integrated telemanagement program based on an integrated health care model in patients with type 2 diabetes mellitus: A prospective study (Preprint)
    Minting Lu, Jiewei Huang, Xueyan Liu, Qingling Chen, Peiru Zhou, Yanmei Yu, Yuling Hu · 2023
  85. Impacto de los esquemas de simplificación en pacientes con diabetes mellitus tipo 2 e inadecuado control metabólico: estudio pragmático emparejado
    Fernando Carrera Viñoles, Javier Rosendo Avila, Daniel Santiago, Natacha Vilera, Zully Andreína Réquiz, Paul Camperos · 2023 · Diabetes actual
  86. ANALYZING LIPID PROFILE CORRELATION AMONG DIABETIC PATIENTS: ASSESSING POTENTIAL RISK REDUCTION FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Dr Maryam Mehmood Dr Jaweria Sana, Dr Mumtaz Ali, Dr Kamlesh Kumar Ahuja, Dr Prince Misri Khan Kalhoro, Dr Vishamer Lal, Dr Deepak Lal · 2024
  87. Efeitos da liraglutida em pacientes com diabetes tipo 2 e obesidade
    Brunna Chaves de Fraga, Melissa Cardoso Deuner · 2024 · Revista JRG de Estudos Acadêmicos
  88. Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
    Ashish Sriram Mishra, M. Vasanthan M. Vasanthan, Bhavna Ghosh, Ponnurengam Malliappan Sivakumar · 2025 · Current Medicinal Chemistry
  89. Management
    Iram Hussain, Janice MacLeod, Fredrick Dunn, Perry E. Bickel, Marconi Abreu, Nicole McNulty, Ildiko Lingvay, Asra Kermani, Marconi Abreu · 2020 · American Diabetes Association eBooks
  90. Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide
    Xi Tan, Brenna L. Brady, Lin Xie, Yurek Paprocki · 2025 · Diabetes Therapy
  91. Beyond bariatrics: A systematic review and meta-analysis of glucagon-like peptide-1 receptor agonists and novel anti-obesity medications in critical care settings
    Shibu Sasidharan, B. L. Lahareesh · 2025 · Global Journal of Health Sciences and Research
  92. Perspective Chapter: A Critical Overview of Metformin Use from Past to Present
    Ahmet Hakan Türk, Hakkı Can Kılıç · 2026 · Pharmaceutical science.
  93. Cost-Effectiveness of Highly Effective Glucose-Lowering Agents: Do Current Practices Optimize Clinical and Economic Outcomes?
    Meredith M. Hoog, Alice Minghetti, William J. Valentine · 2026 · Diabetes Therapy
  94. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    聡 前川, Hiroshi Maegawa, Yasushi Ishigaki, Jakob LANGER, Ai Saotome‐Nakamura, Marc Andersen, Japan Diabetes Clinical Data Management (JDDM) Study Group · 2020 · Institutional Repositories DataBase (IRDB)
  95. Distúrbios do metabolismo dos hidratos de carbono na síndrome dos ovários policísticos
    Cristiano Roberto Grimaldi Barcellos · 2019 · Femina
  96. Pharmacological Mechanisms of Once-Weekly GLP-1 Receptor Agonists for Type 2 Diabetes Management
    Md Afaque Ali, Sani Das, Rajiv Ranjan Kumar, Kumar Rabindra · 2026 · International Journal of Innovative Science and Research Technology (IJISRT)